Skip to main content

Artificial pancreas systems

30-11-2022 | Artificial pancreas systems | News

Real-world data show reduced diabetes burden in young closed-loop users

Real-world use of hybrid closed-loop insulin delivery is associated with improved glycemic control and sleep quality, as well as reduced fear of hypoglycemia in children and young people with type 1 diabetes, shows a UK study.

23-09-2022 | EASD 2022 | Conference coverage | News

Bolus timing requires more attention in people using advanced technologies for type 1 diabetes

Delayed prandial insulin boluses are common in people using advanced technologies for the management of type 1 diabetes and are associated with adverse glycemic outcomes, suggest real-world study results.

Illustration showing CGM communicating with Insulin Pump

20-09-2022 | EASD 2022 | Conference coverage | News

​​​​​​​Fully closed-loop control boosts TIR in insulin-treated type 2 diabetes

A fully closed-loop insulin delivery system markedly increases time in range for people with insulin-treated type 2 diabetes, shows a small randomized crossover trial.

07-09-2022 | Pathogenesis | News

CLOuD: Early and sustained closed-loop therapy does not stave off beta-cell decline

Starting young people on closed-loop insulin delivery within 21 days after type 1 diabetes diagnosis does not slow the decline in their C-peptide levels over the next 12 months, report the CLOuD investigators.

07-09-2022 | Artificial pancreas systems | News

AHCL system benefits people with poorly controlled type 1 diabetes

Use of the MiniMed 780G advanced hybrid closed-loop system leads to greater reductions in glycated hemoglobin levels than conventional treatment in people with poorly controlled type 1 diabetes, ADAPT study data show.

06-09-2022 | Artificial pancreas systems | News

Closed-loop control may support neurodevelopment in adolescents

Improved glycemic control with hybrid closed-loop insulin delivery may facilitate the typical neurodevelopmental changes that occur during adolescence for those with type 1 diabetes, suggests a proof-of-concept trial.

06-07-2022 | Artificial pancreas systems | News

Hybrid closed-loop system brings benefits even with lax bolusing

Use of the Tandem Control IQ hybrid closed-loop insulin delivery system improves time in range even for users who very rarely bolus for meals or to treat hyperglycemia, an observational study suggests.

13-06-2022 | Artificial pancreas systems | News

Researchers calculate unannounced snack threshold for closed-loop system

Children and adolescents using an advanced hybrid closed-loop system for type 1 diabetes can tolerate an unannounced snack containing 20 g of carbohydrate without excessive blood sugar fluctuations, Italian researchers report.